UPDATE: US presidential contender Clinton unveils plans to curb 'outrageous' drug prices

23 September 2015
2019_biotech_test_vial_discovery_big

Hillary Clinton, the frontrunner Democratic presidential candidate in the USA, has said that, if elected, she would implement programs to force the pharmaceutical industry to concede tens of billions of dollars a year in tax breaks, lower prices and increase research spending.

She outlined details of her plan on Tuesday at a community forum in Des Moines, Iowa. However, ahead of this on Monday, Mrs Clinton’s “tweet” about drug “price gouging” being “outrageous,” wiped $15 billion from the value of US biotechnology stocks.

One proposal put forward by Mrs Clinton would limit how much patients could have to spend out of pocket for drugs to $250 a month, or $3,000 a year. It is an idea that builds on policy in the Affordable Care Act limiting total out-of-pocket medical spending to $6,600 a year for an individual, and $13,200 for a family, noted a Bloomberg report.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology